StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report report published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00. The stock has a market cap of $6,000.00, a PE ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- How to Most Effectively Use the MarketBeat Earnings Screener
- MarketBeat Week in Review – 4/22 – 4/26
- What does consumer price index measure?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What to Know About Investing in Penny Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.